Last updated: 2026-09-08 05:12:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
AtriCure, Inc. (ATRC) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $51.56, with a market capitalization of $2.62B and a P/E ratio of 248.35. Over the past 52 weeks, its price has ranged from $25.36 to $53.50. This page covers its latest market performance, valuation, price trends and company information.
$2.62B | |
$52.03 | |
$89.18 | |
$1.00 | |
$52.46 | |
613.13K | |
901.88K | |
248.35 | |
$53.50 | |
$25.36 | |
-- | |
-- |
AtriCure, Inc. (ATRC) last closed at $52.46 as of 2026-09-04 23:47:00, unchanged from the previous close of $52.46.
During the latest regular trading session, ATRC traded between $1.00 and $89.18, with a volume of 613.13K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, AtriCure, Inc. (ATRC) moved from $49.27 to $51.56, representing a gain of 4.66% ($2.29).
The stock traded between $46.61 and $53.50 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 792.96 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 93.1%
ATRC is currently trading at $51.56, placing it 93.1% of the way from its 52-week low of $25.36 to its 52-week high of $53.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 1350 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AtriCure, Inc. (ATRC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.